| PI3K/AKT/mTOR signaling in cancer | Lifetime | 146 | US 87 | 98.65 |
| Cancer Genomics and Diagnostics | Lifetime | 641 | US 349 | 98.83 |
| Lung Cancer Treatments and Mutations | Lifetime | 597 | US 283 | 98.71 |
| Cancer, Hypoxia, and Metabolism | Lifetime | 840 | US 400 | 98.00 |
| Advanced Breast Cancer Therapies | Lifetime | 215 | US 103 | 98.24 |
| Chronic Lymphocytic Leukemia Research | Lifetime | 890 | US 416 | 97.90 |
| Cancer-related gene regulation | Lifetime | 831 | US 361 | 96.28 |
| Colorectal Cancer Treatments and Studies | Lifetime | 862 | US 332 | 97.57 |
| HER2/EGFR in Cancer Research | Lifetime | 679 | US 309 | 97.27 |
| Fibroblast Growth Factor Research | Lifetime | 311 | US 136 | 95.59 |
| PARP inhibition in cancer therapy | Lifetime | 683 | US 301 | 92.96 |
| TGF-β signaling in diseases | Lifetime | 724 | US 326 | 91.40 |
| Cancer-related gene regulation | 2021-2025 | 8 | US 4 | 99.28 |
| PI3K/AKT/mTOR signaling in cancer | 2021-2025 | 10 | US 7 | 97.68 |
| Cancer Genomics and Diagnostics | 2021-2025 | 229 | US 109 | 98.26 |
| Lung Cancer Treatments and Mutations | 2021-2025 | 210 | US 83 | 98.61 |
| Fibroblast Growth Factor Research | 2021-2025 | 33 | US 15 | 93.72 |
| HER2/EGFR in Cancer Research | 2021-2025 | 151 | US 56 | 97.74 |
| Ubiquitin and proteasome pathways | 2021-2025 | 141 | US 36 | 94.05 |
| Epigenetics and DNA Methylation | 2021-2025 | 651 | US 213 | 92.36 |
| Peptidase Inhibition and Analysis | 2021-2025 | 324 | US 96 | 93.56 |
| Cholangiocarcinoma and Gallbladder Cancer Studies | 2021-2025 | 414 | US 81 | 93.45 |
| Advanced Breast Cancer Therapies | 2021-2025 | 290 | US 106 | 94.86 |
| Monoclonal and Polyclonal Antibodies Research | 2021-2025 | 661 | US 214 | 91.27 |
| Cancer, Hypoxia, and Metabolism | 2021-2025 | 871 | US 190 | 87.01 |
| PARP inhibition in cancer therapy | 2021-2025 | 410 | US 162 | 88.58 |
| Cancer-related Molecular Pathways | 2021-2025 | 326 | US 124 | 86.04 |
| Colorectal Cancer Treatments and Studies | 2021-2025 | 983 | US 263 | 88.89 |
| Protein Degradation and Inhibitors | 2021-2025 | 800 | US 333 | 86.31 |
| Cancer Mechanisms and Therapy | 2021-2025 | 403 | US 60 | 83.05 |
| Wnt/β-catenin signaling in development and cancer | 2021-2025 | 730 | US 185 | 49.45 |
| Tuberous Sclerosis Complex Research | 2021-2025 | 649 | US 218 | 40.76 |
